FDA staffers raise objections to proposed pathway for compound pharmacies to make seven peptide products, newly released documents show
Documents posted online June 5, 2023, indicate FDA staff did not support allowing compound pharmacies to manufacture seven “popular peptides,” according to a report citing internal FDA personnel views.